These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 21990321)

  • 41. Therapeutic effect of a multi-targeted imidazolium compound in hepatocellular carcinoma.
    Gopalan B; Narayanan K; Ke Z; Lu T; Zhang Y; Zhuo L
    Biomaterials; 2014 Aug; 35(26):7479-87. PubMed ID: 24912819
    [TBL] [Abstract][Full Text] [Related]  

  • 42. ECT2 regulates the Rho/ERK signalling axis to promote early recurrence in human hepatocellular carcinoma.
    Chen J; Xia H; Zhang X; Karthik S; Pratap SV; Ooi LL; Hong W; Hui KM
    J Hepatol; 2015 Jun; 62(6):1287-95. PubMed ID: 25617497
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Mybl2 expression is under genetic control and contributes to determine a hepatocellular carcinoma susceptible phenotype.
    Frau M; Ladu S; Calvisi DF; Simile MM; Bonelli P; Daino L; Tomasi ML; Seddaiu MA; Feo F; Pascale RM
    J Hepatol; 2011 Jul; 55(1):111-9. PubMed ID: 21419759
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Knockdown of FOXK1 inhibited the proliferation, migration and invasion in hepatocellular carcinoma cells.
    Li P; Yu Z; He L; Zhou D; Xie S; Hou H; Geng X
    Biomed Pharmacother; 2017 Aug; 92():270-276. PubMed ID: 28551547
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Insulin-like growth factor-1 receptor inhibition induces a resistance mechanism via the epidermal growth factor receptor/HER3/AKT signaling pathway: rational basis for cotargeting insulin-like growth factor-1 receptor and epidermal growth factor receptor in hepatocellular carcinoma.
    Desbois-Mouthon C; Baron A; Blivet-Van Eggelpoël MJ; Fartoux L; Venot C; Bladt F; Housset C; Rosmorduc O
    Clin Cancer Res; 2009 Sep; 15(17):5445-56. PubMed ID: 19706799
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Connexin32 regulates hepatoma cell metastasis and proliferation via the p53 and Akt pathways.
    Zhao B; Zhao W; Wang Y; Xu Y; Xu J; Tang K; Zhang S; Yin Z; Wu Q; Wang X
    Oncotarget; 2015 Apr; 6(12):10116-33. PubMed ID: 25426556
    [TBL] [Abstract][Full Text] [Related]  

  • 47. miR-615-5p is restrictedly expressed in cirrhotic and cancerous liver tissues and its overexpression alleviates the tumorigenic effects in hepatocellular carcinoma.
    El Tayebi HM; Hosny KA; Esmat G; Breuhahn K; Abdelaziz AI
    FEBS Lett; 2012 Sep; 586(19):3309-16. PubMed ID: 22819824
    [TBL] [Abstract][Full Text] [Related]  

  • 48. MicroRNA-375 targets AEG-1 in hepatocellular carcinoma and suppresses liver cancer cell growth in vitro and in vivo.
    He XX; Chang Y; Meng FY; Wang MY; Xie QH; Tang F; Li PY; Song YH; Lin JS
    Oncogene; 2012 Jul; 31(28):3357-69. PubMed ID: 22056881
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Disruption of xCT inhibits cell growth via the ROS/autophagy pathway in hepatocellular carcinoma.
    Guo W; Zhao Y; Zhang Z; Tan N; Zhao F; Ge C; Liang L; Jia D; Chen T; Yao M; Li J; He X
    Cancer Lett; 2011 Dec; 312(1):55-61. PubMed ID: 21906871
    [TBL] [Abstract][Full Text] [Related]  

  • 50. MUC20 overexpression predicts poor prognosis and enhances EGF-induced malignant phenotypes via activation of the EGFR-STAT3 pathway in endometrial cancer.
    Chen CH; Wang SW; Chen CW; Huang MR; Hung JS; Huang HC; Lin HH; Chen RJ; Shyu MK; Huang MC
    Gynecol Oncol; 2013 Mar; 128(3):560-7. PubMed ID: 23262208
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Direct interaction between surface β1,4-galactosyltransferase 1 and epidermal growth factor receptor (EGFR) inhibits EGFR activation in hepatocellular carcinoma.
    Tang W; Weng S; Zhang S; Wu W; Dong L; Shen X; Zhang S; Gu J; Xue R
    Biochem Biophys Res Commun; 2013 May; 434(3):449-54. PubMed ID: 23583406
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Inhibition of connective tissue growth factor overexpression decreases growth of hepatocellular carcinoma cells in vitro and in vivo.
    Jia XQ; Cheng HQ; Li H; Zhu Y; Li YH; Feng ZQ; Zhang JP
    Chin Med J (Engl); 2011 Nov; 124(22):3794-9. PubMed ID: 22340243
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Effects of high metastatic potential hepatocellular carcinoma cell-binding peptide on the invasion and metastasis of liver cancer].
    Jia WD; Wang W; Tang ZY; Xu GL; Sun HC; Zhou HJ
    Zhonghua Zhong Liu Za Zhi; 2009 Apr; 31(4):241-5. PubMed ID: 19615273
    [TBL] [Abstract][Full Text] [Related]  

  • 54. An integrin beta4-EGFR unit promotes hepatocellular carcinoma lung metastases by enhancing anchorage independence through activation of FAK-AKT pathway.
    Leng C; Zhang ZG; Chen WX; Luo HP; Song J; Dong W; Zhu XR; Chen XP; Liang HF; Zhang BX
    Cancer Lett; 2016 Jun; 376(1):188-96. PubMed ID: 26996299
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Ubiquitin-like protein FAT10 promotes the invasion and metastasis of hepatocellular carcinoma by modifying β-catenin degradation.
    Yuan R; Wang K; Hu J; Yan C; Li M; Yu X; Liu X; Lei J; Guo W; Wu L; Hong K; Shao J
    Cancer Res; 2014 Sep; 74(18):5287-300. PubMed ID: 25056121
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Knockdown of lactate dehydrogenase A suppresses tumor growth and metastasis of human hepatocellular carcinoma.
    Sheng SL; Liu JJ; Dai YH; Sun XG; Xiong XP; Huang G
    FEBS J; 2012 Oct; 279(20):3898-910. PubMed ID: 22897481
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Regulation of 15-hydroxyprostaglandin dehydrogenase expression in hepatocellular carcinoma.
    Castro-Sánchez L; Agra N; Llorente Izquierdo C; Motiño O; Casado M; Boscá L; Martín-Sanz P
    Int J Biochem Cell Biol; 2013 Nov; 45(11):2501-11. PubMed ID: 23954207
    [TBL] [Abstract][Full Text] [Related]  

  • 58. RUNX3-Regulated GALNT6 Promotes the Migration and Invasion of Hepatocellular Carcinoma Cells by Mediating O-Glycosylation of MUC1.
    Gao F; Zheng G
    Dis Markers; 2022; 2022():2959846. PubMed ID: 35909886
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Erlotinib and sorafenib in an orthotopic rat model of hepatocellular carcinoma.
    Sieghart W; Pinter M; Dauser B; Rohr-Udilova N; Piguet AC; Prager G; Hayden H; Dienes HP; Dufour JF; Peck-Radosavljevic M
    J Hepatol; 2012 Sep; 57(3):592-9. PubMed ID: 22634341
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The O-glycosylating enzyme GALNT2 suppresses the malignancy of gastric adenocarcinoma by reducing EGFR activities.
    Hu WT; Yeh CC; Liu SY; Huang MC; Lai IR
    Am J Cancer Res; 2018; 8(9):1739-1751. PubMed ID: 30323967
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.